Clinical Trial Update: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating eltrombopag for immune thrombocytopenia occurring in patients with chronic lymphoproliferative disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Immune Thrombocytopenia
• Non-hodgkin Lymphoma

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Fondazione Progetto Ematologia | Conditions: Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED